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Abstract
Background: Patients’ adherence to malaria treatment is an important factor in determining the therapeutic
response to anti-malarial drugs. It contributes to the patient’s complete recovery and prevents the emergence of
parasite resistance to anti-malarial drugs. In Brazil, the low compliance with malaria treatment probably explains the
large number of Plasmodium vivax malaria relapses observed in the past years. The goal of this study was to
estimate the proportion of patients adhering to the P. vivax malaria treatment with chloroquine + primaquine in
the dosages recommended by the Brazilian Ministry of Health.
Methods: Patients who were being treated for P. vivax malaria with chloroquine plus primaquine were eligible for
the study. On the seventh day of taking primaquine, they were visited at their home and were interviewed. The
patients were classified as probably adherent, if they reported having taken all the medication as prescribed, in the
correct period of time and dosage, and had no medication tablets remaining; probably non-adherent, if they
reported not having taken the medication, in the correct period of time and dosage, and did not show any
remaining tablets; and certainly non-adherent, if they showed any remaining medication tablets.
Results: 242 of the 280 patients reported having correctly followed the prescribed instructions and represented a
treatment adherence frequency (CI95%) of 86.4% (81.7%-90.1%). Of the 38 patients who did not follow the
recommendations, 27 (9.6%) were still taking the medication on the day of the interview and, therefore, still had
primaquine tablets left in the blister pack. These patients were then classified as certainly non-adherent to
treatment. Although 11 patients did not show any tablets left, they reported incorrect use of the prescribed
therapy regimen and were considered as probably non-adherent to treatment.
Conclusions: Compliance with the P. vivax malaria treatment is a characteristic of 242/280 patients in the surveyed
region. However, the group of non-adherent patients can have an impact on the magnitude of transmission and
relapses of P. vivax infections currently observed in the studied area. Simple practices can be introduced in the
healthcare services in order to improve compliance with the treatment prescribed.
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Background
In 2010, 306,908 cases of malaria were recorded in Bra-
zil, 85% of which were caused by Plasmodium vivax.
The majority (99.7%) of such cases occurred in the
Amazon Region [1], where P. vivax infections are trea-
ted with a chloroquine plus primaquine regimen.
Although this regimen is effective in different dosages
and/or duration of treatment for P. vivax malaria [2],
several studies have reported therapy failures including
those conducted in the Brazilian Amazon region [3,4].
An unsuccessful malaria treatment can be determined
by factors related to the patient, the parasite, and the
treatment itself. Regarding patient-related aspects, it has
been emphasized the patients’ adherence to the treat-
ment as an important factor in determining the thera-
peutic response to anti-malarial drugs, when a large
number of treatments occur without medical supervi-
sion [5]. It contributes to the patient’sc o m p l e t er e c o v -
ery and prevents the emergence of parasite resistance to
anti-malarial drugs. In Brazil, the low compliance with
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P. vivax malaria relapses observed in the past years.
This fact is more significant in areas with an unstable
population, since it becomes difficult to follow up on
patients during treatment, thus confirming the observa-
tions of Duarte and Gyorkos (2003), who emphasized
low adherence to treatment as an important factor in
predicting subsequent episodes of malaria in the same
individual [6].
Several factors are associated with low adherence to
the treatment of malaria. The most emphasized factors
are bad instructions or patient not understanding the
treatment instructions, patient forgetting to take the
medication, disintegration or loss of the medication
tablets, occurrence of side effects [7] and, in some
instances, use of alcohol concomitantly with the medica-
tion, which was observed mainly in camping, settlement,
and mining areas (Pereira, EA personal information). In
the case of drugs such as chloroquine, which induce a
quick clinical improvement with few adverse effects, the
disappearance of the symptoms is also cited as an
important reason for the early suspension of the treat-
ment with primaquine [8]. Inadequate prescription and
dispensing of anti-malarials by health professionals are
recognized as important causes of the low adherence to
anti-malarial treatment [9]. Studies performed to evalu-
ate the use of primaquine to prevent relapses of P. vivax
malaria have considered that such information is neces-
sary to develop strategies for the rational use and con-
trol of anti-malarial drugs [7,10].
The main goal of this study was to estimate the pro-
portion of patients adhering to the P. vivax malaria
treatment with chloroquine + primaquine (in the
dosages recommended by the Brazilian Ministry of
Health) among patients from five municipalities in the
Amazon region. The secondary goal of the study was to
describe the patient reports on the information they
received at the community health center during medica-
tion prescription and dispensing procedures.
Methods
Areas of study
The study was conducted in the Amazon state of Pará,
in the municipalities of Alenquer, Goianesia do Pará,
Itaituba, Maraba, and Santarem, where high incidence of
malaria has been reported in the past years. In addition
to the high incidence of malaria, the selection of these
municipalities also took into account the accessibility
and infrastructure of the healthcare services that provide
diagnosis and treatment of the disease at local level.
Patients in the study
The sample size was determined using an expected low
adherence proportion of 20% [6], with significance level
of 95%, and precision level of 5%. Therefore, the study
would require the participation of 240 patients. Since it
was not possible to predict the number of patients who
were out of home at the time of the visit, the sample
size was increased by 20% in order to compensate for
this expected loss. A total sample of 288 patients was
required at baseline.
The participating patients submitted complete infor-
mation on home address and met the following criteria:
age 6 months old or older; living within the area where
the study was conducted; received recent treatment for
P. vivax monoinfection according to recommendations
made by the Brazilian Ministry of Health, at the com-
munity health centre where they were first diagnosed;
agreed to participate in the study; did not show serious
signs or symptoms of severe malaria; were not pregnant,
if woman; did not report any serious heart, liver, or kid-
ney disease; had no history of allergies to the medica-
tions used in the treatment of P. vivax malaria; and did
not live in the same residence as another patient already
included in this study. All patients, including children,
took tablets of chloroquine, as there is no liquid formu-
lation of chloroquine available in Brazil.
The protocol standardized by the Amazon Network
for the Surveillance of Anti-malarial Drug Resistance–
Amazon Malaria Initiative was used in order to evaluate
adherence to treatment, which can be summarized as an
interview with the patient and verification of the num-
ber of remaining primaquine tablets on the day follow-
ing the projected date for completion of treatment [11].
An interview data form was applied and filled out by
two trained interviewers who were not members of the
local healthcare team. These interviews gathered data on
the patients’ identification and medical history; their
knowledge about malaria; instructions and care received
at the community health centre where they were treated;
compliance with the prescription received; reasons for
an eventual failure to adhere to the treatment; adverse
reactions to the treatment; current clinical status; and
number of remaining anti-malarial untaken tablets at
the visit. The checking for remaining tablets was made
to both chloroquine and primaquine.
Research procedures
Between June 2008 and July 2009 the records of patients
who started treatment for P. vivax malaria in the pre-
vious week were monitored daily in the community
health centres, and those who reached the seventh day
of the medication - corresponding to the last dose of
primaquine - were visited at their homes. After signing
informed consent forms they were interviewed by one of
the team members. For underage patients, the father or
person responsible for the child had to sign the
informed consent form.
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remaining tablets of medication, the patients were classi-
fied as: probably adherent, if the patient reported having
taken all the medication as prescribed, in the correct
period of time and dosage, and had no medication
tablets remaining; probably non-adherent, if they
reported not having taken the medication as prescribed,
in the correct period of time and dosage, and did not
show any remaining tablets; and certainly non-adherent,
if the patient showed any remaining medication tablets.
All of the stages of this research were performed with-
out interfering with the work routine at the community
health centers, since the adherence-related variables are
a direct function of the conditions of prescription and
dispensing of medication. The community health cen-
tre’s staff responsible for the diagnosis and treatment of
malaria did not participate in the activities proposed for
this research. The community healthcare agents in the
area where the patients resided contributed only with
information on how to locate the patients’ homes.
Ethical considerations
The protocol for the study was evaluated and approved
by the Research Ethics Committee of the Fundação de
Medicina Tropical do Amazonas [Amazon Tropical
Medicine Foundation] under Opinion No. 3534/2002.
Those patients who showed malaria symptoms during
the interview were referred to the community health
centres for medical re-evaluation. Those patients who
reported non-adherence to the therapy instructions or
still had medication tablets, were instructed to return to
the community health centre if their symptoms recur.
Result analysis procedures
Data were analysed in Epidata Analysis, version
2.2.1.171. Pearson’s chi-square test with Yates correction
was used to determine the relationship or association
between categorical variables. A significance level of
95% was considered for all of the tests. For analysis of
the factors associated with treatment adherence, patients
classified as probably non-adherent were considered as
certainly non-adherent, thus resulting in just two result
groups for the study: adherent and non-adherent to
treatment.
Results
Two hundred and eighty (280) patients participated in
this study, representing 97.2% of the calculated sample.
They were interviewed in the municipalities of Alenquer
(18.6%), Goianésia do Pará (24.3%), Itaituba (22.9%),
Marabá (20.7%), and Santarém (13.5%). The patients
were treated at community health centres located in
rural, mining, settlement, and camping areas (62%), and
sometimes in urban areas as well (Table 1). All of them
were treated with chloroquine (total dosage: 25 mg/kg,
divided over 3 days) and primaquine (0.5 mg/kg/day, for
7 days).
The majority of the participants were male (66.4%),
with ages ranging from 6 months to 65 years, with a
mean (SD) age of 24.8 (16.2) years. Patients over 15
years old accounted for 68.9% of the interviews. In gen-
eral, the questions posed during the interviews were
answered by the patients themselves. For 27.2% patients
the questions were answered by mother or those
responsible for them. When asked about the way
malaria is transmitted, most of the patients stated that
the disease is transmitted by a mosquito (Table 1).
Regarding the care received at the healthcare centres
where they were treated for malaria, 280 patients
answered that they did not receive any explanation
about the disease and that they were not seen by a phy-
sician. 248 (88.6%) patients stated that they received
both written and verbal instructions on the prescribed
treatment, and 32 (11.4%) stated that they received just
verbal instructions. However, almost all subjects
Table 1 Demographic and knowledge on malaria
transmission characteristics of 280 patients infected with
Plasmodium vivax and treated with chloroquine +
primaquine in Brazilian Amazon
Characteristics n %
Municipality of residence Alenquer 52 18.6
Goianésia do Pará 68 24.3
Itaituba 64 22.9
Marabá 58 20.7
Santarém 38 13.5
Local of treatment Hospital 24 8.5
Emergence room 15 5.4
Primary Care Unit 67 23.9
Rural Health Care
Center
173 61.8
Others 1 0.4
Age (years) <1 4 1.4
1-4 24 8.6
5-9 29 10.4
10-14 30 10.7
≥ 15 193 68.9
Gender Male 186 66.4
Female 94 33.6
Person who answered the interview Patient 204 72.8
Responsible for the
child
76 27.2
Knowledge on how malaria is
transmitted
By mosquitos 254 90.7
By water 7 2.5
Do not know 19 6.8
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verbal (97.9%) instructions. Regarding the compliance
with the recommendations on medication dosage and
schedule, 242 (86.4%) patients reported having correctly
followed the instructions. On the possible adverse effects
of the prescribed drugs, 278 (99.3%) patients stated that
they did not receive any type of instruction from the
person prescribing the medication (Table 2).
Of the 38 patients who did not follow the recommen-
dations, 27 (9.6%) were still taking the medication on
the day of the interview and, therefore, still had prima-
quine tablets left in the blister pack. These patients were
then classified as certainly non-adherent to treatment.
Although 11 patients did not show any tablets left, they
reported incorrect use of the prescribed therapy regimen
and were considered as probably non-adherent to treat-
ment. Therefore, 242 of the 280 patients represented a
treatment adherence frequency (CI95%) of 86.4%
(81.7%-90.1%) (Table 3). This adherence was 100% in
Santarém and Alenquer, and varied in the other partici-
pating municipalities: Itaituba (84.4%), Goianésia do
Pará (77.9%), and Marabá (77.6%). It is noteworthy that
primaquine was the medication that all 27 of the afore-
mentioned patients had left at the time of the interview
and the maximum number of primaquine tablets left
did not exceed four.
When asked about the reason for not following the
treatment as recommended, 22 (81.5%) of the 27 cer-
tainly non-adherent patients responded that they had
forgotten to take the medication. The other five (18.5%)
patients stated that it was due to the side effects of the
medication, meaning worsening of the malaria symp-
toms, itching, and dyspepsia, or because they opted for
consuming alcoholic beverages and were afraid to keep
taking the drugs (Table 3).
The analysis of the factors associated with non-adher-
ence to treatment showed that of the 38 certainly non-
adherent (n = 27) and probably non-adherent (n = 11)
patients, 31 (81.6%) were male, which represented a
4.4:1 male to female ratio. The proportion of certainly
non-adherent patients was 16.7% (31/186) among males,
and the probability of non-adherence among males was
higher than among females (OR = 2.49; CI95%: 1.05-
5.88; p = 0.05). Patients over 15 years old were not dif-
ferent in adherence proportion when compared to
younger ones (OR = 1.54; CI 95%: 0.72-3.33; p =0 . 3 5 ) .
Of the 32 patients who only received verbal instructions,
9 (28.1%) did not adhere to the treatment. Among the
248 patients instructed both verbally and in writing, the
non-adherence rate was just 11.7%, and such difference
was statistically significant (OR = 2.96; CI 95%: 1.25-
7.00; p = 0.02) (Table 4).
Discussion
In this study, the patients’ adherence to the P. vivax
malaria treatment with chloroquine for 3 days + prima-
quine for 7 days were quantified in five municipalities in
the Brazilian Amazon. A rate of 86.4% of adherent
patients was observed, higher than that found by other
research authors in Peru (62.2%) and Ecuador (65.9%), Table 2 Reports of the received and understood
instructions by patients infected with Plasmodium vivax
and treated with chloroquine + primaquine in Brazilian
Amazon
Reports n %
Instructions received about dosage and
schedule
Writen and
verbal
248 88.6
Verbal only 32 11.4
Information received about side effects Yes 2 0.7
No 278 99.3
Comprehension of the written instructions Yes 246 99.2
No 2 0.8
Comprehension of the verbal instructions Yes 274 97.9
No 6 2.1
Correct followed all the prescribed
instructions
Yes 242 86.4
No 38 13.6
Table 3 Adherence classification of the patients infected
with Plasmodium vivax and treated with chloroquine +
primaquine in Brazilian Amazon
n%
Classification Probably adherent 242 86.4
Probably adherent 242 86.4
Certainly non-adherent 27 9.7
Reason for non-adherence Forgetfulness 22 81.5
Side effects 4 14.8
Use of alcohol beverage 1 3.7
Table 4 Factors associated to adherence to the P.vivax
malaria treatment with chloroquine + primaquine in the
Brazilian Amazon
Variables Adherence n (%) OR CI 95% p value
No Yes
Gender
Male 31 (16.7) 155 (83.3) 2.49 1.05 - 5.88 0.05
Female 7 (7.4) 87 (92.6)
Age(years)
>1 5 28 (15.2) 156 (83.3) 1.54 0.72 - 3.33 0.35
≤ 15 10 (10.4) 86 (92.6)
Type of instructions received about dosage and schedule
Verbal only 9 (28.1) 23 (71.9) 2.96 1.25 - 7.00 0.02
Writen +verbal 29 (11.7) 219 (88.3)
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luation [8,12]. In addition, the probable adherence rate
was also higher than that found in Sri Lanka (73.8%)
[13], Ecuador (58%) [12], and Venezuela (76.3%) [14].
Since professional workers responsible for diagnosing
and treating the malaria did not participate in the study,
and the patients were not aware that they would be vis-
ited at home during the treatment, it is unlikely that the
presence of the research team on site would have influ-
enced the behaviour of the participants in regard to
adherence to treatment.
Studies to measure the compliance with the treatment
of P. vivax malaria with chloroquine for 3 days and pri-
maquine for 7 or 14 days, have been conducted in sev-
eral countries in the Amazon region. However, there is
more information available on the traditional therapy
regimen primaquine for 14 days [15]. In general, adher-
ence is lower for longer therapy regimens, when com-
pared with the primaquine regimen for 7 days, thus
reinforcing the premise that the longer the treatment,
the shorter the adherence to such treatment [6,15].
The short duration of the therapy regimen with pri-
maquine must be the explanation for a better adherence
observed in this study. In fact, another study conducted
in Mato Grosso, Brazil also found patient adherence
rates of 84%, including patients with both P. vivax and
P. falciparum infections [6]. Likewise, results of studies
conducted in other regions also showed higher adher-
ence levels for shorter and simpler therapy regimens [5].
Relative accessibility, free treatment, standardization of
treatment regimens, and medication provided at the
healthcare centre where the diagnosis was made, in con-
junction with the repetitive use due to malaria relapses,
are other factors which may contribute to the higher
adherence rated found in Brazil. In this context, it is
known that good prescription and dispensing of drugs
and patient education are recognized as essential ele-
ments for a good adherence to anti-malarial treatment
[7,10].
Although the sample in this study had a larger num-
ber of male patients, female patients showed signifi-
cantly higher adherence to treatment. This difference
has been previously observed [16]. Curiously, no associa-
tion between adherence and the age of the patients was
observed; although it is expected that children and
elderly patients tend to be more adherent to therapy
recommendations, as already observed in other studies
[17].
Under adequate conditions, written therapy recom-
mendation, associated or not with verbal instructions, is
expected to improve adherence to treatment [18]. This
fact was observed here, even when considering the low
proportion of patients treated without adequate written
treatment instructions. It is possible that the repetitive
use of anti-malarial drugs due to disease relapses has
reduced the need for written prescription instructions
for these cases.
It is important not to neglect the 13.6% of non-adher-
ent patients in these series and to reflect on the prob-
able causes of non-adherence. Several contributing
aspects for low adherence to anti-malarial treatment are
described, among which one can highlight social and
economic situation, cultural factors, low education level,
and patient care conditions provided at healthcare cen-
tres. In addition, there are several other factors with
both positive and negative effects on the anti-malarial
treatment compliance [12]. It is estimated that the posi-
tive effects can be the result of factors such as knowl-
edge about the disease, perception of the potential risks
for worsening of the disease, trust in the medication,
ease of administering the drug, shorter treatment time,
and participation of healthcare agents in monitoring the
treatment. On the other hand, factors such as the quick
disappearance of symptoms, occurrence of adverse reac-
tions, fluctuations in the local population numbers, easy
access to self-medication, difficult access to healthcare
services, and bad quality of treatment provided, can
have a negative effect on the adherence to treatment.
Side effects of the drugs used in the treatment of
malaria have been cited as the main reason for low
adherence, mainly in cases of P. falciparum malaria¸
whose treatment until the 1990s was done using a com-
bination of quinine and antibiotics [9]. This was not the
case in the present study, since the side effects are not
very frequent when using chloroquine + primaquine for
P. vivax malaria, in spite of the fact that some patients
stated that adverse reactions were the cause of their
non-adherence to treatment. The use of chloroquine is
enough to alleviate the symptoms in the first 24 hours
of treatment, although a radical cure of the infection
can only occur after the round of primaquine treatment
is completed. The patient’s lack of knowledge about the
slower primaquine hypnozoitocidal effect, in conjunction
with the lack of adequate prescription instructions, may
result in the early suspension of the drugs and also con-
stitute a negative influence on adherence.
Factors not assessed in this study could be speculating
as the cause of the occurrence of non-adherence to
treatment with primaquine. For example, it is common
in the Amazon region eating wild foods such as “açai”,
leading to discontinuation of treatment with primaquine,
because they believe that food is incompatible with pri-
maquine. However, this popular practice is more com-
mon in Marajo Island, located in northern Pará, far
from the region where the study was conducted.
A differentiated pattern of non-adherence to treatment
was observed among the municipalities studied. This
could have been due to the general characteristics of the
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(Marabá, Goianésia do Pará, and Itaituba) are areas of
high population fluctuation caused by several settle-
ments, camping sites and mining sites. Under these con-
ditions, low education level, alcoholism, and little
concern with heath-related issued are common; and all
such conditions are associated with low adherence to
the treatment of malaria [19].
Conclusion
The results presented herein show that although adher-
ence to treatment is a characteristic of most patients
with P. vivax malaria in the surveyed region, a certain
percentage of such patients do not comply with therapy
instructions. This group of non-adherent patients can
have an impact on the magnitude and relapses of P.
vivax infections currently observed in the studied area.
Therefore, some simple practices can be introduced to
in the healthcare services in order to improve compli-
ance with the treatment prescribed. For example, a
check list containing all the steps to be taken to ensure
the good quality of the orientation during patient care
would be a valuable instrument for the healthcare provi-
der, so he or she would not run the risk of forgetting
crucial information such as the need to fully complete
the therapy regimen.
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